JAZZ Long Call Strategy
JAZZ (Jazz Pharmaceuticals plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ (Jazz Pharmaceuticals plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $14.58B, a trailing P/E of 487.62, a beta of 0.27 versus the broader market, a 52-week range of 103.6-235, average daily share volume of 1.0M, a public-listing history dating back to 2007, approximately 3K full-time employees. These structural characteristics shape how JAZZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.27 indicates JAZZ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 487.62 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a long call on JAZZ?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current JAZZ snapshot
As of May 15, 2026, spot at $228.38, ATM IV 32.20%, IV rank 11.60%, expected move 9.23%. The long call on JAZZ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on JAZZ specifically: JAZZ IV at 32.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a JAZZ long call, with a market-implied 1-standard-deviation move of approximately 9.23% (roughly $21.08 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JAZZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JAZZ should anchor to the underlying notional of $228.38 per share and to the trader's directional view on JAZZ stock.
JAZZ long call setup
The JAZZ long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JAZZ near $228.38, the first option leg uses a $230.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JAZZ chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JAZZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $230.00 | $8.15 |
JAZZ long call risk and reward
- Net Premium / Debit
- -$815.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$815.00
- Breakeven(s)
- $238.15
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
JAZZ long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on JAZZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$815.00 |
| $50.50 | -77.9% | -$815.00 |
| $101.00 | -55.8% | -$815.00 |
| $151.49 | -33.7% | -$815.00 |
| $201.99 | -11.6% | -$815.00 |
| $252.48 | +10.6% | +$1,433.49 |
| $302.98 | +32.7% | +$6,482.98 |
| $353.47 | +54.8% | +$11,532.48 |
| $403.97 | +76.9% | +$16,581.98 |
| $454.46 | +99.0% | +$21,631.48 |
When traders use long call on JAZZ
Long calls on JAZZ express a bullish thesis with defined risk; traders use them ahead of JAZZ catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
JAZZ thesis for this long call
The market-implied 1-standard-deviation range for JAZZ extends from approximately $207.30 on the downside to $249.46 on the upside. A JAZZ long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current JAZZ IV rank near 11.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JAZZ at 32.20%. As a Healthcare name, JAZZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JAZZ-specific events.
JAZZ long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JAZZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JAZZ alongside the broader basket even when JAZZ-specific fundamentals are unchanged. Long-premium structures like a long call on JAZZ are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current JAZZ chain quotes before placing a trade.
Frequently asked questions
- What is a long call on JAZZ?
- A long call on JAZZ is the long call strategy applied to JAZZ (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With JAZZ stock trading near $228.38, the strikes shown on this page are snapped to the nearest listed JAZZ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JAZZ long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the JAZZ long call priced from the end-of-day chain at a 30-day expiry (ATM IV 32.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$815.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JAZZ long call?
- The breakeven for the JAZZ long call priced on this page is roughly $238.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JAZZ market-implied 1-standard-deviation expected move is approximately 9.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on JAZZ?
- Long calls on JAZZ express a bullish thesis with defined risk; traders use them ahead of JAZZ catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current JAZZ implied volatility affect this long call?
- JAZZ ATM IV is at 32.20% with IV rank near 11.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.